• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Challenges and prospects of LAG-3 inhibition in advanced gastric and gastroesophageal junction cancer: insights from the RELATIVITY-060 trial.

作者信息

Seghers Sofie, Domen Andreas, Prenen Hans

机构信息

Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium.

Center for Oncological Research (CORE), University of Antwerp, Wilrijk, Belgium.

出版信息

J Gastrointest Oncol. 2024 Dec 31;15(6):2735-2738. doi: 10.21037/jgo-24-757. Epub 2024 Dec 27.

DOI:10.21037/jgo-24-757
PMID:39816014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11732350/
Abstract
摘要

相似文献

1
Challenges and prospects of LAG-3 inhibition in advanced gastric and gastroesophageal junction cancer: insights from the RELATIVITY-060 trial.晚期胃癌和胃食管交界癌中LAG-3抑制的挑战与前景：来自RELATIVITY-060试验的见解
J Gastrointest Oncol. 2024 Dec 31;15(6):2735-2738. doi: 10.21037/jgo-24-757. Epub 2024 Dec 27.
2
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.纳武利尤单抗和雷莫芦单抗联合化疗治疗胃或胃食管结合部腺癌：RELATIVITY-060 期研究。
J Clin Oncol. 2024 Jun 10;42(17):2080-2093. doi: 10.1200/JCO.23.01636. Epub 2024 May 9.
3
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.既往和一线免疫治疗对来自RELATIVITY-020研究的黑色素瘤患者的基线免疫生物标志物的影响以及对纳武利尤单抗和瑞派替尼联合治疗的肿瘤微环境调节作用。
J Immunother Cancer. 2025 Feb 25;13(2):e009773. doi: 10.1136/jitc-2024-009773.
4
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.纳武利尤单抗和雷莫芦单抗治疗抗程序性死亡-1/程序性死亡配体 1 治疗后进展的晚期黑色素瘤患者：RELATIVITY-020 试验的 I/IIa 期结果。
J Clin Oncol. 2023 May 20;41(15):2724-2735. doi: 10.1200/JCO.22.02072. Epub 2023 Feb 13.
5
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.新辅助纳武利尤单抗或纳武利尤单抗联合 LAG-3 抑制剂 relatlimab 治疗可切除食管/胃食管交界处癌：一项 Ib 期试验和 ctDNA 分析。
Nat Med. 2024 Apr;30(4):1023-1034. doi: 10.1038/s41591-024-02877-z. Epub 2024 Mar 19.
6
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.Relatlimab 和 Nivolumab 对比 Nivolumab 用于未经治疗的晚期黑色素瘤。
N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
7
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study.纳武利尤单抗联合疗法用于晚期胃癌和胃食管交界癌患者：II期FRACTION胃癌研究
ESMO Open. 2025 Feb;10(2):104107. doi: 10.1016/j.esmoop.2024.104107. Epub 2025 Jan 10.
8
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.单独使用或联合使用纳武利尤单抗时 LAG-3 阻断抗体 relatlimab 的临床前特征
Cancer Immunol Res. 2022 Oct 4;10(10):1175-1189. doi: 10.1158/2326-6066.CIR-22-0057.
9
Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.纳武利尤单抗/雷莫芦单抗：不可切除或转移性黑色素瘤免疫检查点抑制剂治疗的新选择。
Ann Pharmacother. 2023 Jun;57(6):738-745. doi: 10.1177/10600280221131396. Epub 2022 Oct 21.
10
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.在RELATIVITY-022研究中，纳武利尤单抗联合瑞派替尼用于复发或进展性B细胞恶性肿瘤患者。
Blood Adv. 2025 Mar 3. doi: 10.1182/bloodadvances.2024015086.

引用本文的文献

1
Differential Expression of Immune Checkpoints TIM-3, LAG-3, TIGIT, and Siglec-7 on Circulating Natural Killer Cells - Insights from Healthy Donors Compared to Gastric Cancer Patients.循环自然杀伤细胞上免疫检查点TIM-3、LAG-3、TIGIT和Siglec-7的差异表达——来自健康供体与胃癌患者对比的见解
Oncol Res Treat. 2025 Apr 3:1-16. doi: 10.1159/000545429.

本文引用的文献

1
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial.替雷利珠单抗联合化疗对比安慰剂联合化疗一线治疗晚期胃或胃食管结合部腺癌：RATIONALE-305 随机、双盲、III 期临床试验。
BMJ. 2024 May 28;385:e078876. doi: 10.1136/bmj-2023-078876.
2
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.纳武利尤单抗和雷莫芦单抗联合化疗治疗胃或胃食管结合部腺癌：RELATIVITY-060 期研究。
J Clin Oncol. 2024 Jun 10;42(17):2080-2093. doi: 10.1200/JCO.23.01636. Epub 2024 May 9.
3
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development.
胃癌免疫抑制微环境异质性：对治疗开发的启示。
Trends Cancer. 2024 Jul;10(7):627-642. doi: 10.1016/j.trecan.2024.03.008. Epub 2024 Apr 9.
4
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
5
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.信迪利单抗联合化疗治疗不可切除的胃或胃食管结合部癌：ORIENT-16 随机临床试验。
JAMA. 2023 Dec 5;330(21):2064-2074. doi: 10.1001/jama.2023.19918.
6
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于 HER2 阴性晚期胃癌（KEYNOTE-859）：一项多中心、随机、双盲、III 期临床试验。
Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21.
7
LAG3 in gastric cancer: it's complicated.LAG3 在胃癌中的作用：错综复杂。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10797-10811. doi: 10.1007/s00432-023-04954-1. Epub 2023 Jun 14.
8
LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics.LAG-3 在多种恶性肿瘤中的转录组表达模式：对精准免疫治疗的启示。
Cancer Med. 2023 Jun;12(12):13155-13166. doi: 10.1002/cam4.6000. Epub 2023 May 3.
9
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.胃癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Oct;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. Epub 2022 Jul 29.
10
Recent Estimates and Predictions of 5-Year Survival in Patients with Gastric Cancer: A Model-Based Period Analysis.近期胃癌患者 5 年生存率的估计和预测：基于模型的时间分析。
Cancer Control. 2022 Jan-Dec;29:10732748221099227. doi: 10.1177/10732748221099227.